GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer
Shots:
- GSK reported data from the P-III (FIRST-ENGOT-OV44)study evaluating Jemperli + SoC Pt.-based CT and Zejula maintenance with or without bevacizumab in 1L treatment of stage III or IV nonmucinous epithelial ovarian cancer
- The study met its 1EP (n=1138) of PFS in Arm 2 (385) evaluating SoC CT followed by Zejula maintenance and in Arm 3 (n=753) evaluating SoC CT and Jemperli followed by Zejula and Jemperli maintenance (Bevacizumab can be added across all the arms)
- The study 2EPs are OS, PFS2, time to first & second subsequent therapy, the key 2EP OS does not meet statistical significance and currently, the study is ongoing, demonstrating a consistent safety and tolerability
Ref: GSK | Image: GSK
Related News:- GSK’s Jemperli (dostarlimab) Secures the US FDA’s Breakthrough Therapy Designation to Treat Rectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
